Sudo Biosciences, a company focused on developing precision TYK2 inhibitors, has initiated a Phase 1 clinical trial for SUDO-550. This novel drug is an orally administered, brain-penetrant, allosteric TYK2 inhibitor designed to treat neuroinflammatory diseases. This marks the second allosteric TYK2 inhibitor from Sudo Biosciences to enter clinical trials this year, following SUDO-286, a topical treatment for psoriasis currently in two Phase 1 trials.

The ongoing Phase 1 trial for SUDO-550 aims to assess its safety, tolerability, and pharmacokinetics in healthy volunteers. A crucial aspect of this study is confirming the compound’s ability to effectively cross the blood-brain barrier, a critical factor for treating diseases of the central nervous system. This trial represents a significant step in developing SUDO-550 as a leading brain-penetrant TYK2 inhibitor. This therapy holds promise for advancing treatment options for conditions such as multiple sclerosis, ALS, and Alzheimer’s disease.

Sudo Biosciences is developing several highly potent and selective small molecule TYK2 pseudokinase inhibitors. These inhibitors target a range of autoimmune and neurological conditions. SUDO-550 exhibits high selectivity and potency for TYK2, minimizing off-target effects. Preclinical studies indicate excellent blood-brain barrier penetration, highlighting its potential for treating CNS diseases characterized by neuroinflammation. This positions SUDO-550 as a potentially best-in-class treatment for various neuroinflammatory diseases.

SUDO-286, another key compound in Sudo’s pipeline, is a potent and selective topical TYK2 inhibitor being explored for psoriasis and other immune-mediated skin conditions. It entered clinical trials earlier this year with two ongoing Phase 1 studies involving healthy volunteers and patients.

Sudo Biosciences is dedicated to developing novel medicines to improve patients’ lives. Their programs focus on the tyrosine kinase 2 (TYK2) pseudokinase domain, a vital component in cytokine signaling pathways linked to various immune-mediated inflammatory diseases. Their pipeline includes SUDO-550, the brain-penetrant candidate for multiple sclerosis and neurodegenerative diseases, and SUDO-286, the topical candidate for dermatological conditions. The company operates across the US and UK, with headquarters in Carmel, Indiana.

Source link: http://www.businesswire.com/news/home/20241202300740/en/Sudo-Biosciences-Announces-First-Participants-Dosed-in-Phase-1-Trial-of-Brain-Penetrant-Allosteric-TYK2-Inhibitor-SUDO-550

SUDO-550: the facts in one place

  • Sponsor: Sudo Biosciences
  • Mechanism: Orally administered, brain-penetrant allosteric TYK2 (tyrosine kinase 2) inhibitor; reduces TYK2 activity allosterically, modulating IL-12, IL-23, and Type I interferon signaling
  • Indication studied: Neuroinflammatory diseases; primarily multiple sclerosis (MS); potential for ALS and Alzheimer’s disease
  • Phase: Phase 1 completed; Phase 2 planned
  • Primary endpoint: Safety, tolerability, and pharmacokinetics including blood-brain barrier penetration confirmation in healthy volunteers
  • Headline result: Favorable safety and tolerability; once-daily pharmacokinetic profile; full CNS penetration; over 90% inhibition of TYK2-mediated signaling in CNS and peripheral circulation
  • Registry identifier: ISRCTN13177674
  • Current status: Phase 1 completed with positive topline results; Phase 2 study in MS planned to initiate in first half of 2026
  • First participants dosed in Phase 1 trial: December 2, 2024
  • Positive Phase 1 topline results announced: October 28, 2025
+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.